Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesImpact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma
Biology of Blood and Marrow Transplantation, 09/15/09
Fenske TS et al. – Pre-transplant rituximab is associated with a lower rate of progression and improved survival after AuHCT for DLBCL, with no evidence of impaired engraftment or increased NRM.
Methods- Outcomes of 994 patients receiving AuHCT for DLBCL between 1996 and 2003 were analyzed according to whether rituximab was or was not administered with front-line or salvage therapy before AuHCT
- +R cohort had superior progression-free survival and overall survival at 3 years
- Platelet and neutrophil engraftment not affected by exposure to rituximab
- Nonrelapse mortality (NRM) did not differ significantly between 2 cohorts
- +R cohort had improved PFS
Related Articles
Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach
Hematological Oncology, 10/27/09
Relevance Score: 95%
Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy
Annals of Oncology, 11/16/09
Relevance Score: 94%
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma
Leukemia and Lymphoma, 11/04/09
Relevance Score: 94%
High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma
Leukemia and Lymphoma, 10/30/09
Relevance Score: 94%
Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study
Journal of Clinical Oncology, 10/02/09
Relevance Score: 94%
Today in BMT/SCT...keeping you current
Receive free subspecialty "5-minute updates" via email
Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomes
Bone Marrow Transplantation, 12/03/09
Dermatologic manifestations of hematopoietic stem cell transplantation: understanding and management
Expert Review of Dermatology, 12/03/09
Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut points to determine low, intermediate and high risk groups: The flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC
Biology of Blood and Marrow Transplantation, 12/03/09
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Concurrent diagnoses of Hodgkin lymphoma and biclonal myeloma in the bone marrow
Annals of Diagnostic Pathology, 12/04/09
Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience
Acta Haematologica, 12/04/09
Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome
Journal of Clinical Oncology, 12/04/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor